newsfilter
← Latest News
Business Wire·

Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026

  • Scholar Rock (NASDAQ: SRRK) will report third quarter 2026 financial results on Tuesday, November 10, 2026, before market open.
  • A conference call & webcast with management is scheduled for 8:00 a.m. ET on the same day.
  • The live webcast will be accessible via the "Events and Presentations" section of the Scholar Rock investor website, with an archived replay available for approximately 90 days.
  • The company is commercializing ISEMBLYD (apitegromab-mstn) in the U.S. for patients aged 2 years & older with spinal muscular atrophy (SMA) who are receiving SMN2-targeted treatment, following FDA approval in September 2026.
  • Scholar Rock plans to expand ISEMBLYD access globally in up to 50 countries.
  • The company focuses on muscle-targeted treatments for SMA & other rare neuromuscular diseases using a proprietary platform to develop novel monoclonal antibodies that modulate protein growth factors.
  • Contact information for investors includes Laura Ekas, Ph.D., & for media includes Jeff Smith & Molly MacLeod, Ph.D.